Analyst Research

Report Title Price
Provider: ValuEngine, Inc.
$25.00
Provider: Pechala's Reports
$15.00
Provider: Pechala's Reports
$25.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Soligenix Inc Grants Soligenix Orphan Drug Designation For SGX94 For Treatment Of Acute Radiation Syndrome


Monday, 16 Sep 2013 07:00am EDT 

Soligenix Inc announced that the Office of Orphan Products Development of the US Food and Drug Administration (FDA) has granted orphan drug designation to the active ingredient SGX94 for the treatment of acute radiation syndrome (ARS). SGX94 is an innate defense regulator (IDR), a new class of short, synthetic peptides that accelerates resolution of tissue damage following exposure to a variety of agents including bacterial pathogens, trauma, radiation and/or chemotherapy. 

Company Quote

1.98
0.02 +1.02%
24 Oct 2014